Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist.

[1]  T. Harada,et al.  Development of the new potent non-peptide gpIIb/IIIa antagonist NSL-95301 by utilizing combinatorial technique , 1997 .

[2]  T. Harada,et al.  A Novel Peptide Motif for Platelet Fibrinogen Receptor Recognition* , 1996, The Journal of Biological Chemistry.

[3]  Y. Hayashi,et al.  Design and synthesis of new antagonist peptides for platelet GPIIb/IIIa receptor as anti-thrombotic agents , 1996 .

[4]  J. Tschopp,et al.  Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. , 1994, Journal of medicinal chemistry.

[5]  R J Lynch,et al.  Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. , 1992, Journal of medicinal chemistry.

[6]  C. E. Peishoff,et al.  Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides. , 1992, Journal of medicinal chemistry.

[7]  M. Mulkerrin,et al.  Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins. , 1992, Biochemistry.

[8]  R. Hynes,et al.  Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons , 1992, Cell.

[9]  V. Garsky,et al.  Proton NMR assignments and secondary structure of the snake venom protein echistatin. , 1991, Biochemistry.

[10]  R. Calvo,et al.  Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. , 1991, Journal of medicinal chemistry.

[11]  G. Wagner,et al.  Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. , 1991, Science.

[12]  Tur-Fu Huang,et al.  Disintegrins: A Family of Integrin Inhibitory Proteins from Viper Venoms , 1990, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  B. Coller.  Platelets and thrombolytic therapy. , 1990, The New England journal of medicine.

[14]  E Ruoslahti,et al.  New perspectives in cell adhesion: RGD and integrins. , 1987, Science.

[15]  A. Otaka,et al.  Studies on peptides. CLV. Evaluation of trimethylsilyl bromide as a hard-acid deprotecting reagent in peptide synthesis. , 1987, Chemical & pharmaceutical bulletin.

[16]  Richard O. Hynes,et al.  Integrins: A family of cell surface receptors , 1987, Cell.

[17]  R. Houghten,et al.  Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E Ruoslahti,et al.  Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. , 1986, Science.

[19]  E Ruoslahti,et al.  The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[21]  R. B. Merrifield.  Solid phase peptide synthesis. I. the synthesis of a tetrapeptide , 1963 .

[22]  F. Himmelsbach,et al.  Nonpeptidic fibrinogen receptor antagonists , 1994 .

[23]  L. Alig,et al.  Fibrinogen receptor antagonists - a novel class of promising antithrombotics , 1994 .

[24]  R. Sheppard,et al.  Solid phase peptide synthesis : a practical approach , 1989 .

[25]  R. Colman,et al.  Platelets and extracorporeal circulation. , 1982, Biomaterials.